Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

DiaMedica Therapeutics (DMAC) Change in Accured Expenses (2018 - 2019)

DiaMedica Therapeutics' Change in Accured Expenses history spans 2 years, with the latest figure at $227000.0 for Q4 2019.

For Q4 2019, Change in Accured Expenses rose 176.69% year-over-year to $227000.0; the TTM value through Dec 2019 reached $226000.0, down 43.78%, while the annual FY2025 figure was -$892000.0, 135.84% down from the prior year.
Change in Accured Expenses reached $227000.0 in Q4 2019 per DMAC's latest filing, up from $195000.0 in the prior quarter.
In the past five years, Change in Accured Expenses ranged from a high of $409000.0 in Q3 2018 to a low of -$296000.0 in Q4 2018.